Influence of Glomerular Filtration Rate on Non-(1-84) Parathyroid Hormone (PTH) Detected by Intact PTH Assays
|
|
- Hector Reynolds
- 5 years ago
- Views:
Transcription
1 Clinical Chemistry 46: (2000) Endocrinology and Metabolism Influence of Glomerular Filtration Rate on Non-(1-84) Parathyroid Hormone (PTH) Detected by Intact PTH Assays Jean-Hugues Brossard, 1,3 Raymond Lepage, 2,4 Héloïse Cardinal, 1,3 Louise Roy, 1,3 Louise Rousseau, 1 Claude Dorais, 1 and Pierre D Amour 1,3* Background: Commercial intact parathyroid hormone (I-PTH) assays detect molecular form(s) of human PTH, non-(1-84) PTH, different from the 84-amino acid native molecule. These molecular form(s) accumulate in hemodialyzed patients. We investigated the importance of non-(1-84) PTH in the interpretation of the increased I-PTH in progressive renal failure. Methods: Five groups were studied: 26 healthy individuals, 12 hemodialyzed patients, and 31 patients with progressive renal failure subdivided according to their glomerular filtration rate (GFR) into 11 with a GFR between 60 and 100 ml min m 2, 12 with a GFR between 30 and 60 ml min m 2, and 8 with a GFR between 5 and 30 ml min m 2. We evaluated indicators of calcium and phosphorus metabolism and creatinine clearance (CrCl) in the progressive renal failure groups, and the HPLC profile of I-PTH and C-terminal PTH in all groups. Results: Only patients with a GFR <30 ml min m 2 and hemodialyzed patients had decreased Ca 2 and 1,25-dihydroxyvitamin D, and increased phosphate. In patients with progressive renal failure, I-PTH was related to Ca 2 (r 0.66; P <0.0001), CrCl (r 0.61; P <0.001), 1,25-dihydroxyvitamin D (r 0.40; P <0.05), and 25-hydroxyvitamin D (r 0.49; P <0.01) by simple linear regression. The importance of non-(1-84) PTH in the composition of I-PTH increased with each GFR decrease, being 21% in healthy individuals, 32% in progressive renal failure patients with a GFR <30 1 Centre de Recherche et 2 Département de Biochimie du CHUM, Hôpital Saint-Luc, Montreal, Quebec H2X 1P1, Canada. Departments of 3 Medicine and 4 Biochemistry, Université de Montréal, Montreal, Quebec H3C 3J7, Canada. *Address correspondence to this author at: Centre de Recherche du CHUM, Hôpital Saint-Luc, 264 René Lévesque Blvd. East, Montréal, Québec H2X 1P1, Canada. Fax ; rechcalcium@ssss.gouv.qc.ca. Received December 22, 1999; accepted February 28, ml min m 2, and 50% in hemodialyzed patients, with PTH(1-84) making up the difference. Conclusions: As I-PTH increases progressively with GFR decrease, part of the increase is associated with the accumulation of non-(1-84) PTH, particularly when the GFR is <30 ml min m 2. Concentrations of I-PTH 1.6-fold higher than in healthy individuals are necessary in hemodialyzed patients to achieve PTH(1-84) concentrations similar to those in the absence of renal failure American Association for Clinical Chemistry Many commercial intact parathyroid hormone (I-PTH) 5 assays react with circulating molecular form(s) of PTH other than PTH(1-84) (1 3). These molecular form(s) are not recognized by antibodies specific for the sequence 1-12 of the 84-amino acid structure of PTH (4, 5). This does not impair immunoreactivity with the reporter antibody in commercial I-PTH assays because most N-terminal antibodies react with an epitope distal to position 14 (6). In healthy individuals, these non-(1-84) molecular form(s) account for up to 20% of circulating I-PTH immunoreactivity (1) and behave as C-terminal fragment(s), increasing the non-(1-84) relative proportion with hypercalcemia and decreasing it with hypocalcemia (1, 7, 8). In hemodialyzed patients, the non-(1-84) form(s) may account for up to 55% of I-PTH immunoreactivity (2). This increased proportion in renal failure patients is probably best explained by decreased renal clearance of I-PTH molecular form(s) behaving like a C-terminal fragment (1, 2, 9, 10). This accumulation of non-(1-84) PTH in renal failure is pertinent to the increased nonsuppressible frac- 5 Nonstandard abbreviations: I-PTH, intact parathyroid hormone; GFR, glomerular filtration rate; C-PTH, C-terminal fragment of PTH; 25(OH)D, 25-hydroxyvitamin D; 1,25(OH) 2 D, 1,25-dihydroxyvitamin D; and CrCl, creatinine clearance. 697
2 698 Brossard et al.: Intact PTH in Progressive Renal Failure tion of I-PTH found in that condition (2, 3, 11 16) and also to the fact that I-PTH values overestimated parathyroidmediated osseous abnormalities in uremia (17). It is unclear whether non-(1-84) PTH could be important in explaining increases in I-PTH in early renal failure and as the condition progresses. This study was thus planned to study the relationship between glomerular filtration rate (GFR) and non-(1-84) PTH in the genesis and evolution of increasing I-PTH in renal failure. Subjects and Methods Thirty-one patients with progressive renal failure participated in the study. Twenty-six healthy subjects who had participated in parathyroid function and I-PTH HPLC composition studies (1, 8) served as controls. Twelve hemodialyzed patients who also participated in similar studies (2) were used as examples of end-stage renal failure. experimental protocol The protocol was approved by a local ethics committee. All participants signed an informed consent form. All subjects were studied while maintaining their usual diet. Hemodialyzed patients were studied in October, at the end of summer, and progressive renal failure patients were studied in May, at the end of winter. Blood was obtained from all subjects after an overnight fast where water was permitted. A 24-h urine specimen was also obtained from patients with progressive renal failure. Ionized calcium (Ca 2 ), phosphate, alkaline phosphatase, creatinine, I-PTH and C-terminal PTH (C-PTH), 25-hydroxyvitamin D [25(OH)D], 1,25-dihydroxyvitamin D [1,25(OH) 2 D], and creatinine clearance (CrCl) were measured in all patients with progressive renal failure. Most variables were also measured in the other two groups. laboratory methods Ca 2 was measured immediately after blood collection with an ICA 2 ionized calcium analyzer (Radiometer); the interassay CVs for 38 determinations at 0.77 and 1.75 mmol/l were 3.3% and 2.7%, respectively. Serum phosphate, creatinine, and alkaline phosphatase were measured by automated colorimetry (Baxter Paramax). Serum 25(OH)D and 1,25(OH) 2 D were measured by RIA (Dia- Sorin) after extraction with acetonitrile and, for 1,25(OH) 2 D, after chromatography was performed on C 18 and silica cartridges. The within-assay CV for duplicate determinations was 6% for the 25(OH)D assay and 10 14% for the 1,25(OH) 2 D assay. Serum PTH was measured by means of two different PTH assays. The first was a commercial immunoradiometric assay (Allegro Intact PTH; Nichols Institute) initially reported to react only with PTH(1-84) because synthetic PTH(1-34) was not retained by the C-terminal-directed solid-phase antibody and synthetic PTH(39-84) and (39-68) were not recognized by the labeled N-terminal reporter antibody (18). Nonetheless, this and other commercial I-PTH assays (19) have been demonstrated to react with molecular form(s) of PTH other than PTH(1-84) in humans (1 3) and dogs (20, 21) when sera obtained under various calcium concentrations were fractionated by HPLC. In the company s brochure, the stated detection limit of the assay is 0.1 pmol/l. The intraassay CV for duplicates was 3.1%. Serum C-PTH was measured by an in-house C-PTH assay described previously (7, 8). This assay detects predominantly large C-terminal fragments of the hormone, PTH(1-84), being four- to sixfold less reactive on a molar basis than PTH(39-84). The antigenic determinant in this assay is in the region (65-84) of the PTH molecule; therefore, PTH(1-34), PTH(39-68), and PTH(44-68) are nonreactive. The detection limit was 1 pmol/l using 3 SD from the zero calibrator run in quadruplicate in 10 different assays. The intraassay CV at 50% binding was 3.3%. For I- and C-PTH measurements, all patients with progressive renal failure were measured in the same assay. To analyze individual molecular forms of PTH detected by both assays, one pool was prepared from equal volumes of serum from each of the individuals in each of the three subgroups of patients with progressive renal failure, and fractionated once by HPLC. Results from the healthy subjects and patients with end-stage renal failure have been presented previously (1, 2, 8). Serum PTH was first extracted on Sep-Pack Plus C 18 cartridges (Waters Chromatography Division) (22). Samples were eluted with 3 ml of 800 ml/l acetonitrile in 1 g/l trifluoroacetic acid. After evaporation with nitrogen, the residual volume was freeze-dried and reconstituted in 2 ml of 1 g/l trifluoroacetic acid for HPLC analysis. Each sample was then loaded on a C 18 Bondapak analytical column ( mm; Waters), and eluted with a noncontinuous 15 50% linear gradient of acetonitrile in 1 g/l trifluoroacetic acid, delivered at 1.5 ml/min for 65 min by a Bio-Rad Model 2700 HPLC (Bio-Rad). The 1.5-mL fractions were collected in polypropylene tubes precoated with 1 g/l bovine serum albumin in water. After evaporation with nitrogen, each fraction was freeze-dried and reconstituted to 1 ml with 7 g/l bovine serum albumin in water, and appropriate volumes were assayed for I-PTH. Recovery during all these procedures was 85%. Furthermore, PTH(1-84) and PTH(7-84) calibrators, added to hypoparathyroid serum and processed as described, eluted as single peaks at the expected positions, showing that PTH was not degraded during the above procedures. mathematical and statistical analysis Results are presented as means SD. Comparisons between groups were performed by a one-way ANOVA and the Student-Newman-Keuls comparison test for 2 by 2 comparisons. Standard methods were used for simple and multivariate regression analysis. HPLC profiles were corrected to 100% recovery, and the surface under each peak was evaluated by planimetry using the peak-fitting module of Origin 3.5 (Microcal Software).
3 Clinical Chemistry 46, No. 5, Results The characteristics of the groups studied are summarized in Table 1. To better outline differences in relation to GFR, patients with progressive renal failure were subdivided into three groups: GFR between 60 and 100 ml min m 2, between 30 and 60 ml min m 2, and 30 ml min m 2. Sex distribution varied among the groups, and healthy individuals were at least 12 years younger than those with renal failure. As expected from our stratification of patients, each group differed significantly from the others with respect to creatinine or CrCl. Only patients with a CrCl 30 ml min m 2 and hemodialyzed patients had lower mean Ca 2 and 1,25(OH) 2 D values and a higher mean phosphate value. Alkaline phosphatase was higher in all renal failure groups. Patients with CrCl 30 ml min m 2 had a lower 25(OH)D value than hemodialyzed patients. I- and C-PTH increased progressively with each step in GFR decrease. When only patients with progressive renal failure (n 31) were considered (Fig. 1), a positive correlation was found between the GFR and Ca 2 or 1,25(OH) 2 D value, whereas a negative correlation was found between GFR and phosphate, I-PTH, or C-PTH. When only patients with GFR 30 ml min m 2 were considered (n 23), only the negative correlation between the GFR and I-PTH (r 0.469; P 0.024) or C-PTH (r 0.578; P 0.004) values remained significant. Fig. 2 illustrates that I-PTH values were related to Ca 2, CrCl, 1,25(OH) 2 D, and 25(OH)D values by simple linear regression. Similar results were obtained with C- PTH (data not shown). With multivariate analysis, only Ca 2 (r 0.549) and CrCl (r 0.742) remained significantly correlated with I- and C-PTH values when all patients with progressive renal failure were considered. If those with a CrCl 30 ml min m 2 were excluded from the analysis, only CrCl and 25(OH)D values remained correlated with I- and C-PTH concentrations. The HPLC profiles of I-PTH in healthy individuals, the three groups of patients with GFRs from 100 to 30 ml min m 2, and in hemodialyzed patients are illustrated in Fig. 3. The results are expressed as a percentage of total immunoreactivity to outline differences more clearly. Two peaks are identified with the two PTH assays, one comigrating with PTH(1-84) at 53 min, and another one at min in front of PTH(1-84). This latter peak represents 21% of I-PTH immunoreactivity in healthy individuals, 32% in patients with a GFR 30 ml min m 2, and 50% in hemodialyzed patients. The percentage of non-(1-84) PTH correlated with serum creatinine (r ; P ) even when the group of hemodialyzed patients was excluded (r ; P 0.007). With each decrease in GFR (or increase in serum creatinine), non-(1-84) PTH represented a greater proportion of the I-PTH immunoreactivity measured. For a 5-fold increase in PTH(1-84) between healthy subjects and hemodialyzed patients, non-(1-84) PTH increased 18-fold, i.e., a 3.6-fold difference. Discussion This study was designed to evaluate the role of non-(1-84) PTH, detected by commercial intact PTH assays (3), in the evaluation of the increased I-PTH observed in progressive renal failure. Increased I-PTH concentrations have been shown to be closely associated with the osseous abnormalities of secondary hyperparathyroidism in end-stage renal failure (17, 23 26). We demonstrated previously that non-(1-84) PTH behaves as a C-terminal fragment (1) Group characteristics Table 1. Characteristics of groups studied. a Healthy individuals Progressive renal failure, GFR (ml min m 2 ) <30 Hemodialyzed patients Number Sex, F/M 17/9 2/9 6/6 5/3 6/6 Age, years b c d b Weight, kg Ca 2 ( mmol/l) b,e c,f,h,j PO 4 ( mmol/l) d,e,i c,f,h Creatinine ( mol/l) c c,g c,f,h c,f,h,k CrCl ( ml min m 2 ) f f,h Alkaline phosphatase (25 97 U/L) d d d d (OH)D ( nmol/l) l ,25(OH) 2 D ( pmol/l) f,h g,i I-PTH (1 6.8 pmol/l) b c,e c c,f C-PTH ( pmol/l) c c,g c,f,h c,f,h,k a Results are mean SD. Reference ranges for analytes in parentheses. b d Compared with healthy subjects: b P 0.05; c P 0.001; d P e g Compared with patients with GFR between 60 and 100 ml min m 2 : e P 0.05; f P 0.001; g P h,i Compared with patients with GFR between 30 and 60 ml min m 2 : h P 0.001; i P j l Compared with patients with GFR between 5 and 30 ml min m 2 : j P 0.05; k P 0.001; l P ANOVA
4 700 Brossard et al.: Intact PTH in Progressive Renal Failure Fig. 1. Influence of GFR on selected indicators of calcium and phosphorus metabolism in progressive renal failure. Œ, GFR between 60 and 100 ml min m 2 ; f, GFR between 30 and 60 ml min m 2 ; F, GFR 30 ml min m 2. The hatched areas represent the reference ranges. and accumulates in hemodialyzed patients to account for 50% of I-PTH immunoreactivity compared with 20% in healthy individuals (2). We studied five groups of individuals with GFR values ranging from normal to almost nonexistent. This enabled us to study I-PTH composition as a function of the GFR. I- and C-PTH were increased in patients with a GFR between 30 and 100 ml min m 2 even if mean Ca 2, phosphate, 25(OH)D, and 1,25(OH) 2 D values were in the reference ranges. I- and C-PTH concentrations were higher in patients with a GFR 30 ml min m 2 and in hemodialyzed patients, but in these groups, the mean Ca 2 and 1,25(OH) 2 D concentrations were low and the phosphate concentration was increased. The GFR and Ca 2, 1,25(OH) 2 D, I-PTH, and C-PTH were all correlated when all patients with progressive renal failure were considered. Only the correlation between the GFR and I- and C-PTH remained significant when patients with a GFR 30 ml min m 2 were excluded. The main correlations between I- and C-PTH concentrations in progressive renal failure were with Ca 2, CrCl, 25(OH)D, Fig. 2. Variables associated with I-PTH by simple regression analysis in progressive renal failure. Œ, GFR between 60 and 100 ml min m 2 ; f, GFR between 30 and 60 ml min m 2 ; F, GFR 30 ml min m 2. The hatched areas represent the reference ranges. and 1,25(OH) 2 D concentrations by simple regression. Only the correlations with Ca 2 and CrCl remained significant by multivariate analysis when all patients with progressive renal failure were considered, and only the correlations with 25(OH)D and CrCl remained significant when patients with a GFR 30 ml min m 2 were excluded. Our study was performed at the end of winter, and this may explain why 35% of our patients with progressive renal failure had 25(OH)D concentrations below the lower limit of normal and why 25(OH)D was associated with I-PTH concentrations. It remains that the biochemical findings in our patients were similar to those described by others in similar patients (27 31), with minor differences from one study to the other. In particular, the concentration of I-PTH relative to the GFR of the patients is surprisingly similar (28 30) when the same or similar I-PTH assays are used. The composition of I-PTH as a function of the GFR was our main focus. There were minor changes in composition before a GFR 30 ml min m 2 was reached. At this stage, PTH(1-84) had decreased from 79% in healthy individuals to 68% in patients with progressive renal failure, and non-(1-84) had increased from 21% in healthy
5 Clinical Chemistry 46, No. 5, Fig. 3. HPLC profiles of I-PTH (solid lines) and C-PTH (dashed lines) for single pools of sera from healthy individuals (A); patients with GFRs between 60 and 100 ml min m 2 (B), ml min m 2 (C), or 30 ml min m 2 (D); and hemodialyzed patients (E). The elution positions of PTH(7-84) and PTH(1-84) are indicated by arrows from left to right. F, total percentage of all non-(1-84) PTH fractions measured by each assay as a function of the GFR. individuals to 32% in patients with progressive renal failure. The greatest changes were seen in hemodialyzed patients, where PTH(1-84) and non-(1-84) PTH each accounted for one-half of the I-PTH. This means that the accumulation of non-(1-84) PTH becomes a more significant phenomenon in the last stage of progressive renal failure evolution. For an 8-fold increase in total I-PTH between healthy individuals and hemodialyzed patients,
6 702 Brossard et al.: Intact PTH in Progressive Renal Failure there is a 5-fold increase in PTH(1-84) but an 18-fold increase in non-(1-84) PTH. This 3.6-fold difference between PTH(1-84) and non-(1-84) PTH may well represent decreased renal clearance of this C-terminal fragment. It is interesting to note that the difference in C-PTH between healthy individuals and hemodialyzed patients is also 18-fold; this assay reacts predominantly with C-terminal fragments, reinforcing the decreased clearance hypothesis. Overall, our study demonstrated that the GFR influences the composition of I-PTH in progressive renal failure, with non-(1-84) PTH representing a greater proportion of total I-PTH immunoreactivity with each decrease. When renal function is abolished, I-PTH concentrations 1.6-fold higher are required to achieve PTH(1-84) concentration similar to those in healthy subjects. The role of non-(1-84) PTH in the PTH resistance of renal failure remains to be elucidated because theoretically, this large C-terminal fragment could bind to both the classical PTH/PTHrP (32 34) and C-PTH (35) receptors and therefore interfere with PTH(1-84) biological effects. Recent results obtained in vivo in rats suggest that the synthetic fragment PTH(7-84), possibly related to non-(1-84) PTH, is a potent in vivo antagonist of PTH(1-84) (36). The recent introduction of a whole PTH assay free of interference from non-(1-84) PTH should be very helpful in clarifying these issues (37, 38). References 1. Brossard JH, Whittom S, Lepage R, D Amour P. Carboxylterminal fragments of parathyroid hormone are not secreted preferentially in primary hyperparathyroidism as they are in other causes of hypercalcemia. J Clin Endocrinol Metab 1993;77: Brossard JH, Cloutier M, Roy L, Lepage R, Gascon-Barré M, D Amour P. Accumulation of a non-(1-84) molecular form of parathyroid hormone (PTH) detected by intact parathyroid hormone assay in renal failure: importance in the interpretation of PTH values. J Clin Endocrinol Metab 1996;1: Lepage R, Roy L, Brossard JH, Rousseau L, Dorais C, Lazure C, D Amour P. A non-(1-84) PTH circulating fragment interferes significantly with intact PTH measurement by commercial assays in uremic samples. Clin Chem 1998;44: Colford J, Spring J, Johnson T. Data suggesting the presence of a circulating inhibitor to PTH [Abstract]. 10th International Congress of Endocrinology, June 12 15, 1996, San Francisco, CA: Colford JW, Salvate M, MacFarlane G, Sokoll LJ, Levine MA. Isolation and characterization of large molecular weight fragments of PTH [Abstract]. 79th Annual Meeting of the Endocrine Society, June 11 14, 1997, Minneapolis, MN: Segre G, Tregear GW, Potts JT Jr. Development and application of sequence-specific radioimmunoassays for analysis of the metabolism of parathyroid hormone. Methods Enzymol 1981;37: D Amour P, Labelle F, Lecavalier L, Plourde V, Harvey D. Influence of serum Ca concentration on circulating molecular forms of PTH in three species. Am J Physiol 1986;251:E D Amour P, Palardy J, Bashali G, Malette LE, De Léan A, Lepage R. Modulation of circulating parathyroid hormone immunoheterogeneity in man by ionized calcium concentration. J Clin Endocrinol 1992;74: Segre GV, D Amour P, Hultman A, Potts JT Jr. Effects of hepatectomy, nephrectomy, and nephrectomy/uremia on the metabolism of parathyroid hormone in the rat. J Clin Investig 1981;67: D Amour P, Lazure C, Labelle F. Metabolism of radioiodinated carboxylterminal fragments of bovine parathyroid hormone in normal and anephric rats. Endocrinology 1985;117: Rodriguez M, Felsenfeld AJ, Williams C, Pederson JA, Llach F. The effect of long-term intravenous calcitriol administration on parathyroid function in hemodialysis patients. J Am Soc Nephrol 1991;2: Felsenfeld AJ, Rodriguez M, Dunlay R, Llach F. A comparison of parathyroid gland function in hemodialysis patients with different forms of renal osteodystrophy. Nephrol Dial Transplant 1991;6: Ramirez JA, Goodman WG, Gornbein J, Menezes C, Moulton L, Segre GV, Salusky IB. Direct in vivo comparison of calciumregulated parathyroid hormone secretion in normal volunteers and patients with secondary hyperparathyroidism. J Clin Endocrinol Metab 1993;76: Malberti F, Surian M, Cosci P. Effect of chronic intravenous calcitriol on parathyroid function and set point of calcium in dialysis patients with refractory secondary hyperparathyroidism. Nephrol Dial Transplant 1992;7: Messa P, Vallone C, Mioni G, Geatti O, Iturrin D, Passoni N, Gruciatti A. Direct in vivo assessment of parathyroid hormonecalcium relationship curve in renal patients. Kidney Int 1994;46: Sanchez CP, Goodman WG, Ramirez JA, Gales B, Belin TR, Segre GV, Salusky IB. Calcium regulated parathyroid hormone secretion in adynamic renal osteodystrophy. Kidney Int 1995;48: Quarles LD, Lobaugh B, Murphy G. Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 1992; 75: Nussbaum SR, Zahradnik RJ, Lavigne JR, Brennan GL, Nozawa- Ung K, Kim LY, et al. Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 1987;33: Ratcliffe WA, Heath DA, Ryan M, Jones SR. Performance and diagnostic application of a two-site immunoradiometric assay for parathyrin in serum. Clin Chem 1989;35: D Amour P, Rousseau L, Rocheleau B, Pomier-Layrargues G, Huet PM. Influence of Ca concentration on the clearance and circulating levels of intact and carboxylterminal ipth in pentobarbital-anesthetized dogs. J Bone Miner Res 1996;11: Cloutier M, Gagnon Y, Brossard JH, Gascon-Barré M, D Amour P. Adaptation of parathyroid function to IV 1,25-dihydroxyvitamin D 3 or partial parathyroidectomy in normal dogs. J Endocrinol 1997; 155: Bennett HPJ, Solomon S, Goltzman D. Isolation and analysis of human parathyrin in parathyroid tissue and plasma. Biochem J 1981;197: Cohen Solal ME, Sebert JL, Boudailliez B, Marie A, Moriniere P, Gueris J, et al. Comparison of intact, midregion and carboxylterminal assays of parathyroid hormone for the diagnosis of bone disease in hemodialyzed patients. J Clin Endocrinol Metab 1991; 73: Salusky IB, Ramirez JR, Oppenheim W, Gales B, Segre GV, Goodman WG. Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD. Kidney Int 1994;45: Wang M, Hercz G, Sherrard DJ, Maloney NA, Segre GV, Pei Y. Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. Am J Kidney Dis 1995;26:
7 Clinical Chemistry 46, No. 5, Qi Q, Monier-Faugere MC, Geng Z, Malluche HH. Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am J Kidney Dis 1995;26: Pitts TO, Piraino BH, Mitro R, Chen TC, Segre GV, Greenberg A, Puschett JB. Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate and severe renal failure. J Clin Endocrinol Metab 1988;67: Reichel H, Deibert B, Schmidt-Gayk H, Ritz E. Calcium metabolism in early chronic renal failure: implication for the pathogenesis of hyperparathyroidism. Nephrol Dial Transplant 1991;6: St. John A, Thomas MB, Davies CP, Mullan B, Dick I, Hutchison B, Van der Schaff A, Prince RL. Determinants of intact parathyroid hormone and free 1,25-dihydroxyvitamin D levels in mild and moderate renal failure. Nephron 1992;61: Fajtova VT, Sayegh MH, Hickey N, Aliabadi P, Lazarus JM. Le Boff MS. Intact parathyroid hormone levels in renal insufficiency. Calcif Tissue Int 1995;57: Martinez I, Saracho R, Montenegro J, Llach F. A deficit of calcitriol synthesis may not be the initial factor in the pathogenesis of secondary hyperparathyroidism. Nephrol Dial Transplant 1996; 11: Tregear GW, Van Rietschoten J, Greene E, Keutmann HT, Nial HD, Reit B, et al. Bovine parathyroid hormone: minimum chain length of synthetic peptide required for biological activity. Endocrinology 1973;93: Mahaffey JE, Rosenblatt M, Shepard GL, Potts JT Jr. Parathyroid hormone inhibitors. Determination of minimum sequence requirements. J Biol Chem 1979;254: Rosenblatt M, Segre GV, Tyler GA, Shepard GL, Nussbaum SR, Potts JT Jr. Identification of a receptor-binding region in parathyroid hormone. Endocrinology 1980;106: Inomata N, Akiyama M, Kubota N, Jüppner H. Characterization of a novel PTH-receptor with specificity for the carboxyl-terminal region of PTH(1-84). Endocrinology 1995;136: Slatopolsky E, Finch JL, Clay P, Martin D, Sicard G, Gao P, Cantor T. A novel mechanism for skeletal resistance in uremia [Abstract]. J Am Soc Nephrol 1999;10:A John MR, Goodman WG, Gao P, Cantor TL, Salusky IB, Jüppner H. A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure. J Clin Endocrinol Metab 1999;84: Brossard JH, Lepage R, Gao P, Cantor T, Rousseau L, D Amour P. A new commercial whole-pth assay free of interference by non- (1-84) parathyroid hormone fragments in uremic samples [Abstract]. J Bone Miner Res 1999;14:S444.
A non-(1 84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples
Clinical Chemistry 44:4 805 809 (1998) Endocrinology and Metabolism A non-(1 84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in
More informationMasaaki Inaba, 1* Kiyoshi Nakatsuka, 1 Yasuo Imanishi, 1 Masakazu Watanabe, 2 Yuji Mamiya, 2 Eiji Ishimura, 1 and Yoshiki Nishizawa 1.
Clinical Chemistry 50:2 385 390 (2004) Endocrinology and Metabolism Technical and Clinical Characterization of the Bio-PTH (1 84) Immunochemiluminometric Assay and Comparison with a Second-Generation Assay
More informationMarie-Claude Monier-Faugere, Hanna Mawad, and Hartmut H. Malluche
Opposite Effects of Calcitriol and Paricalcitol on the Parathyroid Hormone-(1-84)/Large Carboxy-Terminal- Parathyroid Hormone Fragments Ratio in Patients with Stage 5 Chronic Kidney Disease Marie-Claude
More informationOrigin of parathyroid hormone (PTH) fragments detected by intact-pth assays
European Journal of Endocrinology (2002) 147 123 131 ISSN 0804-4643 EXPERIMENTAL STUDY Origin of parathyroid hormone (PTH) fragments detected by intact-pth assays L Nguyen-Yamamoto, L Rousseau, J-H Brossard,
More informationParathyroid Hormone: New Assays, New Receptors
Parathyroid Hormone: New Assays, New Receptors By Kevin J. Martin, Irme Akhtar, and Esther A. González Accurate measurements of parathyroid hormone (PTH) in plasma are necessary for the assessment, monitoring,
More informationTHE DEVELOPMENT OF improved assays for the measurement
0021-972X/03/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 88(10):4725 4730 Printed in U.S.A. Copyright 2003 by The Endocrine Society doi: 10.1210/jc.2002-021266 Clinical Utility of an Immunoradiometric
More informationNew lessons from old assays: parathyroid hormone (PTH), its receptors, and the potential biological relevance of PTH fragments
Nephrol Dial Transplant (2002) 17: Editorial Comments 1731 Nephrol Dial Transplant (2002) 17: 1731 1736 New lessons from old assays: parathyroid hormone (PTH), its receptors, and the potential biological
More informationCirculating PTH molecular forms: What we know and what we don t
http://www.kidney-international.org & 6 International Society of Nephrology irculating PTH molecular forms: What we know and what we don t P D Amour 1,2 1 Parathyroid Physiology Laboratory, entre de recherche,
More informationBiochemical markers of renal osteodystrophy in pediatric
Kidney International, Vol. 45 (1994), pp. 253 258 Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD ISIDRO B. SALUSKY, JORGE A. RAMIREZ, WILLIAM OPPENHEIM, BARBARA
More informationParathyroid hormone and growth in children with chronic renal failure
Kidney International, Vol. 67 (2005), pp. 2338 2345 Parathyroid hormone and growth in children with chronic renal failure SIMON C. WALLER, DEBORAH RIDOUT, TOM CANTOR, and LESLEY REES Nephro-Urology Unit,
More informationamino terminus of the hormone, detect not only PTH(1-84) Accepted for publication December 13, 2002
Kidney International, Vol. 63 (2003), pp. 1801 1808 CLINICAL NEPHROLOGY EPIDEMIOLOGY CLINICAL TRIALS Similar predictive value of bone turnover using first- and second-generation immunometric PTH assays
More informationIntact Parathyroid Hormone Levels in Renal Insufficiency
Calcif Tissue Int (15) 57:32%335 Calcified Tissue h~emational 15 Springer-Verlag New York Inc. Intact Parathyroid Hormone Levels in Renal Insufficiency V. T. Fajtova, 1 M. H. Sayegh, z N. Hickey, 2 P.
More informationGlycaemic control and serum intact parathyroid hormone levels in diabetic patients on haemodialysis therapy
Nephrol Dial Transplant (2008) 23: 315 320 doi: 10.1093/ndt/gfm639 Advance Access publication 23 October 2007 Original Article Glycaemic control and serum intact parathyroid hormone levels in diabetic
More informationEuropean Journal of Endocrinology (2003) ISSN
European Journal of Endocrinology (2003) 149 301 306 ISSN 0804-4643 CLINICAL STUDY Large carboxy-terminal parathyroid hormone (PTH) fragment with a relatively longer half-life than 1-84 PTH is secreted
More informationKey words: Vitamin D analogues, alfacalcidol, calcitriol, secondary hyperparathyroidism, renal dialysis
Oral cal ORAL CALCITRIOL VERSUS ORAL ALFACALCIDOL FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS RECEIVING HEMODIALYSIS: A RANDOMIZED, CROSSOVER TR IAL Samantha Moe 1, Lori D Wazny 2, Janet
More informationK/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients
http://www.kidney-international.org & 2008 International Society of Nephrology original article see commentary on page 674 K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease
More informationDo We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital
Do We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital E-mail: snigwekar@mgh.harvard.edu March 13, 2017 Disclosures statement: Consultant: Allena, Becker
More informationBone and Mineral. Comprehensive Menu for the Management of Bone and Mineral Related Diseases
Bone and Mineral Comprehensive Menu for the Management of Bone and Mineral Related Diseases Innovation to Assist in Clinical Diagnosis and Treatment DiaSorin offers a specialty line of Bone and Mineral
More informationParathyroid hormone (serum, plasma)
Parathyroid hormone (serum, plasma) 1 Name and description of analyte 1.1 Name of analyte Parathyroid hormone (PTH) 1.2 Alternative names Parathormone 1.3 NMLC code 1.4 Description of analyte PTH is an
More informationComparison between Whole and Intact Parathyroid Hormone Assays
tap_926 42..49 Therapeutic Apheresis and Dialysis 15(Supplement 1):42 49 doi: 10.1111/j.1744-9987.2011.00926.x Therapeutic Apheresis and Dialysis 2011 International Society for Apheresis Comparison between
More informationTherapeutic golas in the treatment of CKD-MBD
Therapeutic golas in the treatment of CKD-MBD Hemodialysis clinic Clinical University Center Sarajevo Bantao, 04-08.10.2017, Sarajevo Abbvie Satellite symposium 06.10.2017 Chronic Kidney Disease Mineral
More informationPART FOUR. Metabolism and Nutrition
PART FOUR Metabolism and Nutrition Advances in Peritoneal Dialysis, Vol. 23, 2007 Alicja E. Grzegorzewska, Monika Mĺot Michalska Serum Level of Intact Parathyroid Hormone and Other Markers of Bone Metabolism
More informationIntroduction. Nephrol Dial Transplant (2012) 27: doi: /ndt/gfr535 Advance Access publication 22 September 2011
Nephrol Dial Transplant (2012) 27: 1950 1956 doi: 10.1093/ndt/gfr535 Advance Access publication 22 September 2011 Interpretation of serum PTH concentrations with different kits in dialysis according to
More informationDifferences in bone turnover and intact PTH levels between African American and Caucasian patients with end-stage renal disease
Kidney International, Vol. 64 (2003), pp. 737 742 Differences in bone turnover and intact PTH levels between African American and Caucasian patients with end-stage renal disease B. PETER SAWAYA, REZKALLA
More informationNIH Public Access Author Manuscript Am J Kidney Dis. Author manuscript; available in PMC 2011 May 1.
NIH Public Access Author Manuscript Published in final edited form as: Am J Kidney Dis. 2010 May ; 55(5): 897 906. doi:10.1053/j.ajkd.2009.12.041. Intact PTH Combined With the PTH Ratio for Diagnosis of
More informationA novel mechanism for skeletal resistance in uremia
Kidney International, Vol. 58 (2000), pp. 753 761 A novel mechanism for skeletal resistance in uremia EDUARDO SLATOPOLSKY, JANE FINCH, PATRICIA CLAY, DANIEL MARTIN, GREGORIO SICARD, GARY SINGER, PING GAO,
More informationSuppressive effect of calcium on parathyroid hormone release in adynamic renal osteodystrophy and secondary hyperparathyroidism
Kidney International, Vol. 5] (1997), pp. 159 1595 Suppressive effect of calcium on parathyroid hormone release in adynamic renal osteodystrophy and secondary hyperparathyroidism WILLIAM G. GOODMAN, JOHANNS
More information( ) , (Donabedian, 1980) We would not choose any treatment with poor outcomes
..., 2013 Amgen. 1 ? ( ), (Donabedian, 1980) We would not choose any treatment with poor outcomes 1. :, 2. ( ): 3. :.,,, 4. :, [Biomarkers Definitions Working Group, 2001]., (William M. Bennet, Nefrol
More informationDifferent effects of calcitriol and parathytoidectomy on the PTH-calcium curve in dialysis patients with severe hyperparathyroidism
Nephrol Dial Transplant (996) : 8-87 Original Article Nephrology Dialysis Transplantation Different effects of calcitriol and parathytoidectomy on the PTH-calcium curve in dialysis patients with severe
More informationCKD: Bone Mineral Metabolism. Peter Birks, Nephrology Fellow
CKD: Bone Mineral Metabolism Peter Birks, Nephrology Fellow CKD - KDIGO Definition and Classification of CKD CKD: abnormalities of kidney structure/function for > 3 months with health implications 1 marker
More informationChapter 3.1: Diagnosis of CKD MBD: biochemical abnormalities Kidney International (2009) 76 (Suppl 113), S22 S49. doi: /ki.2009.
chapter 3.1 http://www.kidney-international.org & 2009 KDIGO Chapter 3.1: Diagnosis of CKD MBD: biochemical abnormalities. doi:10.1038/ki.2009.191 Grade for strength of recommendation a Strength Wording
More informationHyperparathyroidism: Operative Considerations. Financial Disclosures: None. Hyperparathyroidism. Hyperparathyroidism 11/10/2012
Hyperparathyroidism: Operative Considerations Financial Disclosures: None Steven J Wang, MD FACS Associate Professor Dept of Otolaryngology-Head and Neck Surgery University of California, San Francisco
More informationEffects of Diabetes Mellitus, Age, and Duration of Dialysis on Parathormone in Chronic Hemodialysis Patients. Hamid Nasri 1, Soleiman Kheiri 2
Saudi J Kidney Dis Transplant 2008;19(4):608-613 2008 Saudi Center for Organ Transplantation Saudi Journal of Kidney Diseases and Transplantation Original Article Effects of Diabetes Mellitus, Age, and
More informationKobe University Repository : Kernel
Title Author(s) Citation Issue date 2009-09 Resource Type Resource Version DOI URL Kobe University Repository : Kernel Marked increase in bone formation markers after cinacalcet treatment by mechanisms
More informationRace Is a Major Determinant of Secondary Hyperparathyroidism in Uremic Patients
J Am Soc Nephrol 11: 330 334, 2000 Race Is a Major Determinant of Secondary Hyperparathyroidism in Uremic Patients AJAY GUPTA,* LEE R. KALLENBACH, GERARD ZASUWA,* and GEORGE W. DIVINE *Division of Nephrology
More informationSecondary hyperparathyroidism an Update on Pathophysiology and Treatment
Secondary hyperparathyroidism an Update on Pathophysiology and Treatment Klaus Olgaard Copenhagen Budapest Nephrology School August 2007 HPT IN CRF Renal mass Ca 2+ 1,25(OH) 2 D 3 CaR Hyperparathyroidism
More informationchapter 1 & 2009 KDIGO
http://www.kidney-international.org chapter 1 & 2009 DIGO Chapter 1: Introduction and definition of CD MBD and the development of the guideline statements idney International (2009) 76 (Suppl 113), S3
More informationStandardization of DiaSorin and Roche automated third generation PTH assays with an International Standard: impact on clinical populations
DOI 1.1515/cclm-213-127 Clin Chem Lab Med 214; aop Etienne Cavalier *, Pierre Delanaye, Pierre Lukas, Agnes Carlisi, Romy Gadisseur and Jean-Claude Souberbielle Standardization of DiaSorin and Roche automated
More informationAbnormal calcaemic response to PTH in the uraemic rat without secondary hyperparathyroidism
Nephrol Dial Transplant (1996) 11: 1292-1298 Original Article Mephrology Dialysis Transplantation Abnormal calcaemic response to PTH in the uraemic rat without secondary hyperparathyroidism. Berdud, A.
More informationRenal osteodystrophy represents a spectrum of skeletal
Technical Approach to Iliac Crest Biopsy Joel D. Hernandez, Katherine Wesseling, Renata Pereira, Barbara Gales, Rick Harrison, and Isidro B. Salusky Department of Pediatrics, David Geffen School of Medicine
More informationReversal of adynamic bone disease by lowering of dialysate calcium
http://www.kidney-international.org & 26 International Society of Nephrology original article Reversal of adynamic bone disease by lowering of dialysate calcium A Haris 1, DJ Sherrard 2 and G Hercz 3 1
More informationThis review examines the dynamics of parathyroid hormone
In-Depth Review Dynamics of Parathyroid Hormone Secretion in Health and Secondary Hyperparathyroidism Arnold J. Felsenfeld,* Mariano Rodríguez, and Escolástico Aguilera-Tejero *Department of Medicine,
More informationNew biological targets for CKD- MBD: From the KDOQI to the
New biological targets for CKD- MBD: From the KDOQI to the KDIGO Guillaume JEAN, MD. Centre de Rein Artificiel, 42 avenue du 8 mai 1945, Tassin la Demi-Lune, France. E-mail : guillaume-jean-crat@wanadoo.fr
More informationBsml Polymorphism of the Vitamin D Receptor Gene in Hyperparathyroid or Hypoparathyroid Dialysis Patients
Clinical Chemistry / BSMI POLYMORPHISM OF THE VITAMIN D RECEPTOR GENE Bsml Polymorphism of the Vitamin D Receptor Gene in Hyperparathyroid or Hypoparathyroid Dialysis Patients Jacopo Tagliabue, MD,1 Marco
More informationIntroduction/objective: Adinamic bone disease (ABD) is a common finding in peritoneal. dialysis (PD) and is associated with a
Original Article Low-calcium peritoneal dialysis solution is effective in bringing PTH levels to the range recommended by current guidelines in patients with PTH levels < 150 pg/dl Authors Thyago Proença
More informationSensipar. Sensipar (cinacalcet) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.46 Subject: Sensipar Page: 1 of 5 Last Review Date: June 22, 2018 Sensipar Description Sensipar (cinacalcet)
More informationSecondary Hyperparathyroidism: Where are we now?
Secondary Hyperparathyroidism: Where are we now? Dylan M. Barth, Pharm.D. PGY-1 Pharmacy Resident Mayo Clinic 2017 MFMER slide-1 Objectives Identify risk factors for the development of complications caused
More informationHormonalandMineralChangesinEarlyStagesofChronicKidneyDiseases
: F Diseases Volume 16 Issue 2 Version 1.0 Year 2016 Type: Double Blind Peer Reviewed International Research Journal Publisher: Global Journals Inc. (USA) Online ISSN: 2249-4618 & Print ISSN: 0975-5888
More informationChapter 5: Evaluation and treatment of kidney transplant bone disease Kidney International (2009) 76 (Suppl 113), S100 S110; doi: /ki.2009.
http://www.kidney-international.org & 2009 KDIGO Chapter 5: Evaluation and treatment of kidney transplant bone disease ; doi:10.1038/ki.2009.193 Grade for strength of recommendation a Strength Wording
More informationHyperphosphatemia Modestly Retards Parathyroid Hormone Suppression during Calcitriol-Induced Hypercalcemia in Normal and Azotemic Rats
Original Paper Nephron 2002;92:883 888 DOI: 10.1159/000065454 Accepted: May 22, 2002 Hyperphosphatemia Modestly Retards Parathyroid Hormone Suppression during Calcitriol-Induced Hypercalcemia in Normal
More informationRenal Association Clinical Practice Guideline in Mineral and Bone Disorders in CKD
Nephron Clin Pract 2011;118(suppl 1):c145 c152 DOI: 10.1159/000328066 Received: May 24, 2010 Accepted: December 6, 2010 Published online: May 6, 2011 Renal Association Clinical Practice Guideline in Mineral
More informationA calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure Rapid Communication
Kidney International, Vol. 53 (1998), pp. 223 227 A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure Rapid Communication JOHN E. ANTONSEN, DONALD
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Prevalence and Pattern of Mineral Bone Disorder in Chronic Kidney Disease Patients Using Serum
More informationDirect inhibitory effect of calcitriol on parathyroid function
Kidney International, Vol. 36 (1989), pp. 1093 1098 Direct inhibitory effect of calcitriol on parathyroid function (sigmoidal curve) in dialysis ROBERT DUNLAY, MARIANO RODRIGUEZ, ARNOLD J. FELSENFELD,
More informationThe Effect of Long-Term Intravenous Calcitriol Administration on Parathyroid Function in Hemodialysis
The Effect of Long-Term Intravenous Calcitriol Administration on Parathyroid Function in Hemodialysis 12 Mariano Rodriguez,3 Arnold J. Felsenfeld, Carl Williams, James A. Pederson, and Francisco Liach
More informationMonth/Year of Review: September 2012 Date of Last Review: September 2010
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More information4/20/2015. The Neck xt Exploration: Intraoperative Parathyroid Hormone (IOPTH) Testing During Surgical Parathyroidectomy. Learning Objectives
The Neck xt Exploration: Intraoperative Parathyroid Hormone (IOPTH) Testing During Surgical Parathyroidectomy Nichole Korpi-Steiner, PhD, DABCC, FACB University of North Carolina Chapel Hill, NC Learning
More informationCinacalcet treatment in advanced CKD - is it justified?
Cinacalcet treatment in advanced CKD - is it justified? Goce Spasovski ERBP Advisory Board member University of Skopje, R. Macedonia TSN Congress October 21, 2017, Antalya Session Objectives From ROD to
More informationMetabolic Bone Disease Related to Chronic Kidney Disease
Metabolic Bone Disease Related to Chronic Kidney Disease Deborah Sellmeyer, MD Director, Johns Hopkins Metabolic Bone Center Dept of Medicine, Division of Endocrinology Disclosure DSMB member for denosumab
More informationGuidelines for dosing of intravenous calcitriol in dialysis patients with hyperparathyroidism
Nephrol Dial Transplant (16) 11 [Suppl 3]: 6-101 Nephrology Dialysis Transplantation Guidelines for dosing of intravenous calcitriol in dialysis patients with hyperparathyroidism E. Fernandez 1 and F.
More informationSkeletal. Parathyroid hormone-related protein Analyte Information
Skeletal Parathyroid hormone-related protein Analyte Information 1 2012-04-04 Parathyroid hormone related protein (PTHrP) Introduction Parathyroid hormone-related protein (PTHrP) is actually a family of
More informationRadioimmunoassay Specific for Amino (N) and Carboxyl (C) Terminal Portion of Parathyroid Hormone
Endocrinol. Japon. 1975, 22 (6), 471 `477 Radioimmunoassay Specific for Amino (N) and Carboxyl (C) Terminal Portion of Parathyroid Hormone MASAHIRO TANAKA, KAORU ABE, IsAMu ADACHI KEN YAMAGUCHI, SUMIKO
More informationInter-method variability in PTH measurement: Implication for the care of CKD patients
http://www.kidney-international.org & 2006 International Society of Nephrology original article see commentary on page 240 Inter-method variability in measurement: Implication for the care of CKD patients
More informationParicalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients
Pediatr Nephrol (2006) 21:1434 1439 DOI 10.1007/s00467-006-0204-5 ORIGINAL ARTICLE Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients Wacharee Seeherunvong
More informationDavid Bruyette, DVM, DACVIM
VCAwestlaspecialty.com David Bruyette, DVM, DACVIM Disorders of calcium metabolism are common endocrine disorders in both dogs and cats. In this article we present a logical diagnostic approach to patients
More informationNicht-oxidiertes (nox-)pth: ein neuer Marker für CKD-MBD
Biomarker der kardio-renalen Achse Mannheim, 20. Januar 2017 Nicht-oxidiertes (nox-)pth: ein neuer Marker für CKD-MBD Prof. Dr. med. Thomas Bernd Dschietzig Immundiagnostik AG, Bensheim Med. Klinik m.
More informationCa, Mg metabolism, bone diseases. Tamás Kőszegi Pécs University, Department of Laboratory Medicine Pécs, Hungary
Ca, Mg metabolism, bone diseases Tamás Kőszegi Pécs University, Department of Laboratory Medicine Pécs, Hungary Calcium homeostasis Ca 1000g in adults 99% in bones (extracellular with Mg, P) Plasma/intracellular
More informationEffect of percutaneous calcitriol injection therapy on secondary hyperparathyroidism in uraemic patients
Nephrol Dial Transplant (2003) 18 [Suppl 3]: iii42 iii46 DOI: 10.1093/ndt/gfg1011 Effect of percutaneous calcitriol injection therapy on secondary hyperparathyroidism in uraemic patients Kazuhiro Shiizaki
More informationNuove terapie in ambito Nefrologico: Etelcalcetide (AMG-416)
Nuove terapie in ambito Nefrologico: Etelcalcetide (AMG-416) Antonio Bellasi, MD, PhD U.O.C. Nefrologia & Dialisi ASST-Lariana, Ospedale S. Anna, Como, Italy Improvement of mineral and bone metabolism
More informationPATIENTS suffering from hyperparathyroidism caused
0021-972X/98/$03.00/0 Vol. 83, No. 11 Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright 1998 by The Endocrine Society Parathyroid Hormone after Adenectomy for Primary Hyperparathyroidism.
More informationThe Parsabiv Beginner s Book
The Parsabiv Beginner s Book A quick guide to help you learn about your treatment with Parsabiv and what to expect Indication Parsabiv (etelcalcetide) is indicated for the treatment of secondary hyperparathyroidism
More informationORIGINAL ARTICLE. Novel Parathyroid Hormone (1-84) Assay as Basis for Parathyroid Hormone Monitoring in Renal Hyperparathyroidism
ORIGINAL ARTICLE Novel Parathyroid Hormone (1-84) Assay as Basis for Parathyroid Hormone Monitoring in Renal Hyperparathyroidism Klaus Kaczirek, MD; Gerhard Prager, MD; Philipp Riss, MD; Gerald Wunderer,
More informationDIAGNOSING X-LINKED HYPOPHOSPHATEMIA (XLH) BIOCHEMICAL TESTING CONSIDERATIONS
DIAGNOSING X-LINKED HYPOPHOSPHATEMIA (XLH) BIOCHEMICAL TESTING CONSIDERATIONS XLH IS CHARACTERIZED BY CHRONIC HYPOPHOSPHATEMIA XLH is a hereditary, progressive, lifelong disorder. In children and adults,
More informationNephrology Dialysis Transplantation
Nephrol Dial Transplant (1998) 1: [Suppl ]: 68 7 Nephrology Dialysis Transplantation Intermittent oral 1a-hydroxyvitamin D is effective and safe for the suppression of secondary hyperparathyroidism in
More informationProtocol GTC : A Randomized, Open Label, Parallel Design Study of Sevelamer Hydrochloride (Renagel ) in Chronic Kidney Disease Patients.
Protocol GTC-68-208: A Randomized, Open Label, Parallel Design Study of Sevelamer Hydrochloride (Renagel ) in Chronic Kidney Disease Patients. These results are supplied for informational purposes only.
More informationThe role of calcimimetics in chronic kidney disease
http://www.kidney-international.org & 2006 International Society of Nephrology The role of calcimimetics in chronic kidney disease A Gal-Moscovici 1,2 and SM Sprague 1 1 Division of Nephrology and Hypertension,
More informationThe Calcimimetic Agent AMG 073 Lowers Plasma Parathyroid Hormone Levels in Hemodialysis Patients with Secondary Hyperparathyroidism
J Am Soc Nephrol 13: 1017 1024, 2002 The Calcimimetic Agent AMG 073 Lowers Plasma Parathyroid Hormone Levels in Hemodialysis Patients with Secondary Hyperparathyroidism WILLIAM G. GOODMAN,* GERALD A. HLADIK,
More informationCKD-MBD CKD mineral bone disorder
CKD Renal bone disease Dr Mike Stone University Hospital Llandough Affects 5 10 % of population Increasingly common Ageing, diabetes, undetected hypertension Associated with: Cardiovascular disease Premature
More informationPREVALENCE AND PATTERNS OF HYPERPARATHYROIDISM AND MINERAL BONE DISEASE IN PATIENTS WITH CHRONIC KIDNEY DISEASE AT KENYATTA NATIONAL HOSPITAL
PREVALENCE AND PATTERNS OF HYPERPARATHYROIDISM AND MINERAL BONE DISEASE IN PATIENTS WITH CHRONIC KIDNEY DISEASE AT KENYATTA NATIONAL HOSPITAL DR. ANNE MUGERA The Problem Chronic Kidney disease is a worldwide
More informationThe influence of acute and chronic hypercalcemia on the parathyroid hormone response to hypocalcemia in rabbits
European Journal of Endocrinology (2002) 146 411 418 ISSN 0804-4643 EXPERIMENTAL STUDY The influence of acute and chronic hypercalcemia on the parathyroid hormone response to hypocalcemia in rabbits S
More informationComplications of Chronic Kidney Disease: Anemia, Mineral Metabolism, and Cardiovascular Disease
Med Clin N Am 89 (2005) 549 561 Complications of Chronic Kidney Disease: Anemia, Mineral Metabolism, and Cardiovascular Disease Shona Pendse, MD, Ajay K. Singh, MB, MRCP(UK)* Renal Division, Brigham and
More informationKDOQI COMMENTARY VOL 55, NO 5, MAY 2010
VOL 55, NO 5, MAY 2010 KDOQI COMMENTARY KDOQI US Commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD Mineral and Bone Disorder (CKD-MBD) Katrin
More informationCalcium x phosphate product
Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Calcium x phosphate product GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL
More informationCLINICAL PRACTICE GUIDELINE CKD-MINERAL AND BONE DISORDERS (CKD-MBD) Final Version (01/03/2015)
CLINICAL PRACTICE GUIDELINE CKD-MINERAL AND BONE DISORDERS (CKD-MBD) Final Version (01/03/2015) Dr Simon Steddon, Consultant Nephrologist, Guy s and St Thomas NHS Foundation Trust, London Dr Edward Sharples,
More informationNatpara (parathyroid hormone) Prior Authorization with Quantity Limit Program Summary
Natpara (parathyroid hormone) Prior Authorization with Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1 Agent Indication Dosing and Administration Natpara (parathyroid hormone) subcutaneous
More informationChanges in serum osteocalcin levels in the follow-up of kidney transplantation
Original Article Ann Clin Biochem 1997; 34: 651--655 Changes in serum osteocalcin levels in the follow-up of kidney transplantation M R Bonnin", M T Gonzalez-, J M GriIi6 2, J M Cruzado", J Bover-, J M
More informationIncorporating K/DOQI Using a Novel Algorithm Approach: Regina Qu Appelle s Experience
Incorporating K/DOQI Using a Novel Algorithm Approach: Regina Qu Appelle s Experience Michael Chan, Renal Dietitian Regina Qu Appelle Health Region BC Nephrology Days There is a strong association among
More informationTotal Parathyroidectomy with Forearm Autotransplantation as the Treatment of Choice for Secondary Hyperparathyroidism
The Journal of International Medical Research 2011; 39: 978 987 Total Parathyroidectomy with Forearm Autotransplantation as the Treatment of Choice for Secondary Hyperparathyroidism J NARANDA 1,2, R EKART
More informationThe Role of the Laboratory in Metabolic Bone Disease
The Role of the Laboratory in Metabolic Bone Disease Howard Morris PhD, FAACB, FFSc(RCPA) President, IFCC Professor of Medical Sciences, University of South Australia, Clinical Scientist, SA Pathology
More informationORIGINAL ARTICLE. Persistent Parathyroid Hormone Elevation Following Curative Parathyroidectomy for Primary Hyperparathyroidism
Persistent Parathyroid Hormone Elevation Following Curative Parathyroidectomy for Primary Hyperparathyroidism Elizabeth A. Mittendorf, MD; Christopher R. McHenry, MD ORIGINAL ARTICLE Background: Persistent
More informationPathogenesis of secondary hyperparathyroidism
The International Journal of Artificial Organs / Vol. 32 / no. 2, 2009 / pp. 75-80 Review Pathogenesis of secondary hyperparathyroidism MARIO COZZOLINO, SABINA PASHO, GIUDITTA FALLABRINO, LAURA OLIVI,
More informationPersistent post transplant hyperparathyroidism. Shiva Seyrafian IUMS-97/10/18-8/1/2019
Persistent post transplant hyperparathyroidism Shiva Seyrafian IUMS-97/10/18-8/1/2019 normal weight =18-160 mg In HPT= 500-1000 mg 2 Epidemiology Mild 2 nd hyperparathyroidism (HPT) resolve after renal
More informationORIGINAL ARTICLE. Long-term Results of Subcutaneous Parathyroid Grafts in Uremic Patients
ORIGINAL ARTICLE Long-term Results of Subcutaneous Parathyroid Grafts in Uremic Patients Paul Kinnaert, MD; Isabelle Salmon, MD; Christine Decoster-Gervy, PhD; Anne Vienne, PhD; Luc De Pauw, MD; Luc Hooghe,
More informationTHE NEW ZEALAND MEDICAL JOURNAL
THE NEW ZEALAND MEDICAL JOURNAL Vol 116 No 1179 ISSN 1175 8716 Efficacy of an oral, 10-day course of high-dose calciferol in correcting vitamin D deficiency Fiona Wu, Toni Staykova, Anne Horne, Judy Clearwater,
More informationPART FOUR. Metabolism and Nutrition
PART FOUR Metabolism and Nutrition Advances in Peritoneal Dialysis, Vol. 21, 2005 Maria Mesquita, 1 Eric Wittersheim, 2 Anne Demulder, 2 Max Dratwa, 1 Pierre Bergmann 3 Bone Cytokines and Renal Osteodystrophy
More informationORIGINAL ARTICLE. parathyroid graft function after presternal
ORIGINAL ARTICLE Parathyroid Graft Function After Presternal Subcutaneous Autotransplantation for Renal Hyperparathyroidism Miguel Echenique-Elizondo, MD, PhD; Francisco Javier Díaz-Aguirregoitia, MD,
More informationClinical biochemistry of calcium and vitamin D
Clinical biochemistry of calcium and vitamin D Dr Andrew Day Consultant in Clinical Biochemistry and Metabolic Medicine University Hospitals Bristol NHS Trust e-mail: andrew.day@uhbristol.nhs.uk A 48-year
More informationhypercalcemia of malignancy hyperparathyroidism PHPT the most common cause of hypercalcemia in the outpatient setting the second most common cause
hyperparathyroidism A 68-year-old woman with documented osteoporosis has blood tests showing elevated serum calcium and parathyroid hormone (PTH) levels: 11.2 mg/dl (8.8 10.1 mg/dl) and 88 pg/ml (10-60),
More informationGuidelines and new evidence on CKD - MBD treatment
Guidelines and new evidence on CKD - MBD treatment Goce Spasovski ERBP Advisory Board member University of Skopje, R. Macedonia ERA-EDTA CME course IV Congress of Nephrology of B&H, April 25, 2015, Sarajevo,
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Boehm BO, Rosinger S, Belyi D, Dietrich JW. The parathyroid
More information